Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer

B Gao; A Russell; J Beesley; XQ Chen; S Healey; M Henderson; M Wong; C Emmanuel; L Galletta; SE Johnatty; D Bowtell; M Haber; M Norris; P Harnett; G Chenevix-Trench; RL Balleine; A Defazio; D Gertig; A Green; P Webb; J Hung; S Moore; N Traficante; S Fereday; K Harrap; T Sadkowsky; N Pandeya; R Stuart-Harris; F Kirsten; J Rutovitz; P Clingan; A Glasgow; A Proietto; S Braye; G Otton; J Shannon; T Bonaventura; J Stewart; S Begbie; M Friedlander; D Bell; S Baron-Hay; A Ferrier; G Gard; D Nevell; N Pavlakis; S Valmadre; B Young; C Camaris; R Crouch; L Edwards; N Hacker; D Marsden; G Robertson; P Beale; J Beith; J Carter; C Dalrymple; A Hamilton; R Houghton; P Russell; M Links; J Grygiel; J Hill; A Brand; K Byth; R Jaworski; R Sharma; A Achen; G Wain; B Ward; D Papadimos; A Crandon; M Cummings; K Horwood; A Obermair; L Perrin; D Wyld; J Nicklin; M Davy; MK Oehler; C Hall; T Dodd; T Healy; K Pittman; D Henderson; J Miller; J Pierdes; P Blomfield; D Challis; R McIntosh; A Parker; B Brown; R Rome; D Allen; P Grant; S Hyde; R Laurie; M Robbie; D Healy

Journal article

Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer

B Gao, A Russell, J Beesley, XQ Chen, S Healey, M Henderson, M Wong, C Emmanuel, L Galletta, SE Johnatty, D Bowtell, M Haber, M Norris, P Harnett, G Chenevix-Trench, RL Balleine, A Defazio, D Gertig, A Green, P Webb Show all

Scientific Reports | Published : 2014

DOI: 10.1038/srep04669

Download PDF

Abstract

ABCB1 (adenosine triphosphate-binding cassette transporter B1) mediates cellular elimination of many chemotherapeutic agents including paclitaxel, which is commonly used to treat ovarian cancer. A significant association between common single nucleotide polymorphisms (SNPs) in ABCB1 and progression-free survival has been reported in patients with ovarian cancer. Variable paclitaxel clearance due to genotype specific differences in ABCB1 activity in cancer cells and/or normal tissues may underlie the association. Using cell-based models, we evaluated the correlations between ABCB1 expression, polymorphisms, transporter activity and paclitaxel sensitivity in ovarian cancer (n = 10) and lymphob..

View full abstract

University of Melbourne Researchers

David Bowtell Author

Nadia Traficante Author

Julie Fereday Author

Anne Hamilton Author

Related Projects (3)

Molecular Epidemiology of Ovarian Cancer: The Australian Ovarian Cancer Study National Clinical Follow-Up Core

Ovarian cancer is the seventh most common cancer in Australian women and fifth most common cause of cancer death, with approximately 1200 ne..

AUSTRALIAN OVARIAN CANCER STUDY (AOCS): A MULTIDISCIPLINARY OVARIAN CANCER RESOURCE FOR THE GENOMICS ERA

Ovarian cancer is relatively uncommon and is histologically very diverse, making it difficult to analyse ovarian cancer at a molecular level..

Molecular Epidemiology of Ovarian Research Institute

PUBLIC ABSTRACT A major obstacle to preventive strategies for ovarian cancer is the lack of recognized modifiable risk factors. Age, a pos..

Grants

Awarded by Medical Research and Materiel Command

Funding Acknowledgements

This project was supported by the National Health and Medical Research Council (NHMRC) of Australia (scholarship to B.G.), Cancer Institute New South Wales and Cancer Australia (552481). AdeF is funded by the University of Sydney Cancer Research Fund and the Cancer Institute NSW through the Sydney-West Translational Cancer Research Centre.We gratefully acknowledge the cooperation of the institutions that supported the study. We also acknowledge the contribution of Australian Ovarian Cancer Study Group (full list can be found at http://www.aocstudy.org), all study nurses and research assistants and would like to thank all of the women who participated in AOCS. AOCS was supported by U.S. Army Medical Research and Materiel Command DAMD17-01-1-0729, NHMRC Enabling Grant 400413 and Project Grant 400281, the Cancer Council Tasmania and the Cancer Foundation of Western Australia.